AngioDynamics, Inc.
AngioDynamics, Inc. (ANGO) is a medical device company focused on vascular access, interventional oncology, and peripheral vascular disease, with its dominant political signal being $17.1M in physician payments in 2024 (get_political_influence.doctor_payments[0].total_payment_usd) and a single congressional trader executing 7 transactions in 2025.
BusinessWhat ANGO does
AngioDynamics designs, manufactures, and sells medical devices for minimally invasive, image-guided procedures in vascular access, interventional oncology, and peripheral vascular disease. Revenue is derived from product sales in capital equipment, disposables, and services, primarily to hospitals and outpatient centers. The company operates in a highly regulated healthcare sector subject to FDA oversight and reimbursement policies.
12 months past · 3 months futureANGO activity timeline
Lifetime Government AwardsANGO federal contracts by year
Smart Money · 13F HoldingsHedge funds holding ANGO
Politicians Trading ANGOMembers of Congress with recent ANGO positions
Congressional TradesWho in Congress is trading ANGO
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting ANGOLive legislation impacting this stock
Political ProfileWhere ANGO sits in Washington
[object Object]
STRUCTURAL: High regulatory density (85) due to healthcare sector and FDA oversight, with multiple healthcare bills showing impact ratios ~0.0111. EVIDENTIARY: Single congressional trader (W000797) active with 7 transactions in 2025, mixing purchases and sales; two recent corporate insider buys totaling $229.6K (Recent corp insider Form 4 buys); but no lobbying spend, federal contracts, or political donations. Net: Mixed signals with some insider buying but limited political engagement.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Physician payment transparency and scrutiny under Sunshine ActCMS"get_political_influence.doctor_payments shows $17.1M in 2024 payments to physicians, which may attract regulatory attention."
-
FDA regulatory changes for medical device approvals and clearancesFDA"Sector is healthcare with high regulatory density; no specific bill carveouts but general oversight."
Regulatory opportunities
-
Potential reimbursement expansions for interventional oncology proceduresCMS"Recent bill_impacts show multiple healthcare bills with estimated revenue impacts, indicating legislative activity affecting sector."
Capitol Hill AlliesChampions & critics
Congressional champions
- Unknown Unknown
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for ANGO — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades ANGO
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord